Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

June 5, 2025

Study Completion Date

July 9, 2025

Conditions
Non Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerSquamous Non Small Cell Lung CancerLung Cancer
Interventions
DRUG

Domvanalimab

Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

DRUG

Etrumadenant

Etrumadenant is an A2aR and A2bR antagonist

DRUG

Zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Trial Locations (44)

11042

Clinical Research Alliance, Lake Success

Northwell Health Cancer Institute, Lake Success

15224

Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh

22031

Virginia Cancer Specialists, Fairfax

24060

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg

27157

Wake Forest Baptist Health, Winston-Salem

32308

Florida Cancer Specialists - Panhandle, Tallahassee

32605

Florida Cancer Specialists, Gainesville

33401

Florida Cancer Specialists - East, West Palm Beach

34223

Florida Cancer Specialists, Englewood

35294

University of Alabama at Birmingham, Birmingham

37203

Sarah Cannon Research Institute, Nashville

40202

Norton Cancer Institute, Louisville

40503

Baptist Health Lexington, Lexington

70121

Ochsner Clinic Foundation, New Orleans

76104

The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth

77339

Millennium Oncology, Houston

90603

Innovative Clinical Research Institute (ICRI), Whittier

07450

The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion, Ridgewood

Unknown

Border Medical Oncology, Albury

Coffs Harbour Health Campus, Coffs Harbour

Adelaide Cancer Centre, Elizabeth Vale

Shoalhaven Cancer Care Centre, Nowra

McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH), Montreal

Hong Kong United Oncology Centre, Hong Kong

Queen Elizabeth Hospital (Hong Kong), Hong Kong

Curie Oncology, Singapore

Kosin University Gospel Hospital, Busan

Chungbuk National University Hospital (CBNUH), Cheongju-si

Chonnam University Hospital, Hwasun

Gachon University Gil Medical Center, Incheon

Chonbuk National University Hospital, Jeonju

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Kangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

St Vincent Hospital of the Catholic University of Korea, Suwon

Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu-si

Taipei Medical University - Shuang Ho Hospital, New Taipei City

Chi Mei Hospital, Tainan City

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Taipei

Chang Gung Memorial Hospital at Linkou, Taoyuan District

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Arcus Biosciences, Inc.

INDUSTRY

NCT04262856 - Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter